Source link : https://www.newshealth.biz/health-news/fda-approves-durvalumab-for-limited-stage-sclc/
Durvalumab (Imfinzi, AstraZeneca) is now approved for adults with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed after treatment with concurrent platinum-based chemotherapy and radiation therapy. The US Food and Drug Administration approval makes the monoclonal antibody — which is already approved for multiple tumor types — the first immunotherapy regimen approved […]
Author : News Health
Publish date : 2024-12-06 06:52:19
Copyright for syndicated content belongs to the linked Source.